About this document
BiTE Platform for Cancer Immunotherapy by wins1roy is a document available to read on EtoBox.
The document discusses the BiTE (bispecific T-cell engager) platform, particularly focusing on the BiTE antibody blinatumomab, which targets CD19 for cancer immunotherapy. BiTE technology links T-cells with tumor cells to activate an immune response, leading to tumor cell apoptosis. Blinatumomab has shown promising results in treating various B-cell malignancies and has been approved by the FDA for specific leukemia cases.
- Author
- wins1roy
- Language
- EN